RET and pericardial effusion: A 70-year-old woman with RET fusion gene-positive lung cancer cT2bN2M1c (OSS, BRA) stage IVB developed pericardial effusion about 18 months after starting selpercatinib treatment. The patient wished to continue selpercatinib treatment, so the dose was gradually and carefully reduced to 40 mg/day.